Please ensure Javascript is enabled for purposes of website accessibility

Why United Therapeutics Blasted 14% Higher Today

By Eric Volkman – Aug 4, 2021 at 5:56PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Every one of the company's products booked a revenue gain in Q2.

What happened

Specialty pharmaceutical-company United Therapeutics (UTHR 1.05%) was an outlier stock in the best way on Wednesday. After reporting quarterly figures showing revenue growth in all of its products, the shares closed the day over 14% higher.

So what

United Therapeutics took in $446.5 million in revenue for its Q2, which was a very healthy 23% higher year over year. Net income also rose handsomely: On a non-GAAP (adjusted) basis, it advanced by 19% to land at $193.5 million, or $4.09 per share.

Pills spilling out of a bottle and onto U.S. currency.

Image source: Getty Images.

Both results trounced analyst estimates. On average, prognosticators tracking the pharmaceutical stock were expecting merely $378.8 million on the top line and $3.02 in adjusted, per-share net profit.

As mentioned, all of the company's products saw gains across that one-year stretch. Revenue for its foundational drug, pulmonary arterial hypertension (PAH) treatment Remodulin, saw a 17% gain to almost $140 million during the quarter, while Remodulin's peer Tyvaso eclipsed that by shooting nearly 29% higher (to just under $154 million). Pediatric neuroblastoma drug Unituxin nearly doubled its revenue to $53 million.

Now what

While United Therapeutics didn't proffer any guidance in its earnings release, it indicated that the upward momentum of at least some of those drugs should continue. 

The company quoted COO Michael Benkowitz as saying that "we are currently seeing some of the highest levels of referrals of Tyvaso and Orenitram [another PAH treatment] since their launches and we're well on our way to our goal of doubling the number of Tyvaso patients on therapy by the end of 2022."

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

United Therapeutics Stock Quote
United Therapeutics
$276.60 (1.05%) $2.88

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.